Key Points Pfizer’s earnings and stock price soared in early pandemic days thanks to its coronavirus treatment and ...

PFE’s Stock Performance, Rising Estimates & Attractive Valuation. Pfizer’s stock has declined 6.9% in the past year compared with a decrease of 1.6% for the industry.

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer (PFE) concluded the recent trading session at $25.35, signifying a -1.17% move from its prior day's close.

Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially ...

Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over the past decade.

Firstly, let us look at Pfizer’s stock performance in recent years. PFE stock has faced a notable decline of 30% from levels of $35 in early January 2021 to around $25 now, vs. an increase of ...

Pfizer has had its own issues with falling Covid-19 vaccine sales weighing on its stock performance over the recent years. Newsletters Games Share a News Tip. ... While PFE stock looks undervalued ...

Pfizer's recent financial performance shows 14% YoY operational growth excluding COVID sales. Check out more on PFE stock here.